Cerulean Doses First Patient in Phase II Study of CRLX101 Drug

Cerulean Pharma has dosed the first patient in a Phase II study of its investigational CRLX101 drug, designed for the treatment of extensive-stage small cell lung cancer patients sensitive to first-line platinum-based chemotherapy.
Pharmaceutical Business Review